The domain expert's concerns about druggability are valid for conventional small molecule approaches, but they overlook emerging RNA-guided therapeutic modalities that can achieve the precision required for TDP-43 phase separation intervention. I propose that the solution lies not in traditional drug discovery paradigms, but in **leveraging the inherent specificity of RNA secondary structures to create programmable therapeutics that selectively modulate pathological TDP-43-RNA networks**. My ref
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.60
Evidence
0.55
Novelty
0.60
Feasibility
0.00
Impact
0.00
Druggability
0.00
Safety
0.00
Competition
0.00
Data
0.00
Reproducible
0.00
KG Connect
0.50
Score Breakdown
Dimension
Advancing Beyond Traditional D
Mechanistic
0.600
Evidence
0.550
Novelty
0.600
Feasibility
0.000
Impact
0.000
Druggability
0.000
Safety
0.000
Competition
0.000
Data
0.000
Reproducible
0.000
KG Connect
0.500
Evidence
Advancing Beyond Traditional Druggability Through RNA-Guided